|Bid||56.400 x 800|
|Ask||56.390 x 1000|
|Day's Range||56.100 - 57.530|
|52 Week Range||49.960 - 70.050|
|Beta (3Y Monthly)||1.16|
|PE Ratio (TTM)||250.16|
|Earnings Date||Oct 25, 2018|
|Forward Dividend & Yield||1.60 (2.78%)|
|1y Target Est||61.59|
- Growing body of evidence, including real-world studies, points to the clinical significance of anti-citrullinated protein antibody as a biomarker of poor prognosis in pati
Nektar Therapeutics (NKTR) is focused on developing a strong pipeline of product candidates that utilize its polymer conjugate technology platforms. Its research pipeline includes investigational drugs for cancer, autoimmune diseases, and chronic pain. Nektar Therapeutics generated revenues of $1.09 billion in the second quarter of 2018.
A look at who's moving, who's growing and who's dealing in the Bay Area's health care and life sciences space.
Zacks.com highlights: Bristol-Myers Squibb, Celanese, Ternium S.A. and Mettler-Toledo International
Novartis (NVS) is set to release its third quarter of 2018 earnings results on October 18. Analysts are estimating EPS of $1.31 and revenues of $13.02 billion. Novartis, one of the largest pharmaceutical companies by revenue, specializes in the development, manufacturing, and marketing of healthcare products.
AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.
Bristol-Myers (BMY) enters a clinical trial collaboration with Compugen and will make a $12-million equity investment in the latter.
Bristol-Myers Squibb Co said on Friday that its blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy. The drug failed to extend overall survival in patients suffering from small cell lung cancer, an aggressive form of the disease, when compared to patients already on chemotherapy. Opdivo has already been approved to treat several forms of cancer, including skin and lung cancer.
Bristol-Myers Squibb Co. said Friday a late-stage trial of a treatment for small cell lung cancer failed to meet its main goal. The drug company said the Phase 3 study called CheckMate-331 evaluating its opdivo in patients with the disease who relapsed following platinum-based chemotherapy failed to meet its primary endpoint of overall survival. "Small cell lung cancer is a highly aggressive disease in which significant unmet need remains," said Sabine Maier, development lead, thoracic cancers, at Bristol-Myers Squibb. "We are focused on researching innovative oncology therapies to improve outcomes for patients with lung cancer." Shares were slightly higher premarket, but have fallen 6.1% in 2018, while the S&P 500 has gained 2.1%.
Bristol-Myers Squibb Company today announced topline results from the Phase 3 CheckMate -331 study evaluating Opdivo versus the current standard of care, topotecan or amrubicin , in patients with small cell lung cancer who relapsed following platinum-based chemotherapy.
Johnson & Johnson (JNJ) plans to report its third-quarter earnings on October 16. Wall Street analysts expect JNJ to register adjusted EPS of $2.03 in the third quarter, representing YoY (year-over-year) growth of ~6.7%. In comparison, the company reported second-quarter adjusted EPS of $2.10.
In October, 18 analysts are covering Alexion Pharmaceuticals (ALXN) stock. Five of them have recommended a “strong buy,” 11 have recommended a “buy,” and two have recommended a “hold.”
Shares of Compugen Ltd. shot up 17% in premarket trade Thursday, after Bristol-Myers Squibb Co. said it will make a $12 million equity investment as part of a collaboration on a cancer treatment. As part of the agreement, Bristol-Myers will buy about 2.4 million shares at $4.95 a share, which is 52% above Wednesday's closing price of $3.25. The companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's investigational anti-PVRIG antibody, COM701, in combination with Bristol-Myers' immune checkpoint inhibitor Opdivo, in patients with advanced solid tumors. Bristol-Myers' stock fell 1.3% ahead of the open. Year to date, Compugen's stock has soared 30% through Wednesday, while Bristol-Myers shares have slipped 0.8% and the S&P 500 has gained 4.2%.
Bristol-Myers Squibb Co and Israel's Compugen said on Thursday they will collaborate in clinical trials for patients with advanced solid tumours. The trials will evaluate the safety and tolerability of Compugen’s COM701, an investigational antibody, in combination with Bristol-Myers Squibb’s immune checkpoint inhibitor Opdivo. In conjunction with the collaboration, Bristol-Myers Squibb will invest $12 million in Compugen, purchasing 2,424,243 shares - equal to a 4.1 percent stake - at $4.95 each.
Bristol-Myers Squibb Company and Compugen today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen’s COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb’s programmed death-1 immune checkpoint inhibitor Opdivo , in patients with advanced solid tumors.
NEW YORK and HOLON, Israel , Oct. 11, 2018 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration ...
Novartis (NVS) announces positive results from a post hoc analysis of the phase II study, SUSTAIN, on pipeline candidate, crizanlizumab, being published in the American Journal of Hematology.
Alexion Pharmaceuticals’ (ALXN) total operating expenses increased from $602.4 million in the second quarter of 2017 to $1.35 billion in the second quarter of 2018. It generated operating income of $226.7 million in the second quarter of 2017. In the second quarter of 2018, it had an operating loss of $400.1 million.
Alexion Pharmaceuticals (ALXN) is a leader in complement inhibition. It focuses on hematology, nephrology, neurology, and metabolic disorders. In this series, we’ll explore its financials, valuation metrics, latest developments, and analyst recommendations.
Alexion Pharmaceuticals’ (ALXN) revenues increased $132.3 million to $1.04 billion in the second quarter of 2018 compared to the second quarter of 2017. For fiscal 2018 and fiscal 2019, Alexion Pharmaceuticals is expected to generate revenues of $4.04 billion and $4.72 billion, respectively, compared to $3.55 billion in fiscal 2017. Fiscal 2018 gross margins for its peers Abbott Laboratories (ABT), Amgen (AMGN), Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), and Pfizer (PFE) are expected to be 59.10%, 85.94%, 70.09%, 69.64%, and 79.21%, respectively.
Of the total 18 analysts covering Bristol-Myers Squibb (BMY) in October, seven analysts have given the stock a “buy” or higher rating, ten analysts have given it a “hold” rating, and one analyst has given it a “sell” rating. The mean rating for Bristol-Myers Squibb stock is 2.44 with a target price of $60.75.
How Is Bristol-Myers Squibb Positioned in October 2018? Bristol-Myers Squibb (BMY) incurred a cost of product sales of $1.63 billion in the second quarter of 2018 as compared with $1.57 billion in the second quarter of 2017.